Development of novel eIF4E inhibitors to potently and selectively suppress tumor growth across multiple indications

Ribometrix’s eIF4E inhibitors are novel, potent, selective inhibitors of cap-dependent translation leading to anti-tumor activity in multiple cancer indications including, non-small cell lung cancer, colorectal cancer, breast cancer, and melanoma. The combination of our eIF4E inhibitor with standard of care (SOC) synergistically enhances in vivo anti-tumor efficacy, causing tumor regression in many cancer types. Furthermore, combination with our eIF4E inhibitor is able to restore sensitivity to SOC in resistant cells in vitro, suggesting the ability to mitigate drug resistance and restore sensitivity to SOC in treatment resistant populations. IND-enabling studies are underway.